Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
Follow NXL
Nexalin Technology, Inc. (NXL) EV/Sales
As of 16 October 2026, Nexalin Technology, Inc. (NXL) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from −14.2× (October 2023) to 263× (December 2024); the current reading is higher than 35% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.0× | (86.18%) |
| FY2024 | 130× | — |
| FY2023 | −0.2× | — |
| FY2022 | −2.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 27.5× | 80.94% |
| Mar 2026 | 15.2× | (15.46%) |
| Dec 2025 | 18.0× | (76.41%) |
| Sep 2025 | 76.2× | 36.91% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVF INVO Fertility, Inc compare | −0.3× |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| BIOLQ Biolase, Inc. compare | 0.3× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. | 3.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)